Study:
A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML
Rationale:
n/a
Purpose:
The purpose of this study is to assess whether there is a survival benefit with lintuzumab
given in combination with low dose cytarabine versus low dose cytarabine and placebo in
patients with AML.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Acute Myeloid Leukemia |
Drug: Lintuzumab (SGN-33)
Drug: Low dose cytarabine
Drug: Placebo |
Phase 2 |
Verified by
Seattle Genetics, Inc.
October, 2011
Sponsored by: Seattle Genetics, Inc.
Information provided by: Seattle Genetics, Inc.
ClinicalTrials.gov identifier: NCT00528333
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Eric Sievers, MD., Study Director